Analysts Anticipate Kadmon Holdings Inc (KDMN) Will Post Quarterly Sales of $560,000.00

Analysts expect Kadmon Holdings Inc (NYSE:KDMN) to post sales of $560,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Kadmon’s earnings, with the highest sales estimate coming in at $1.04 million and the lowest estimate coming in at $150,000.00. Kadmon posted sales of $2.28 million during the same quarter last year, which suggests a negative year over year growth rate of 75.4%. The company is expected to announce its next earnings results on Thursday, November 8th.

On average, analysts expect that Kadmon will report full-year sales of $2.45 million for the current year, with estimates ranging from $1.04 million to $3.60 million. For the next fiscal year, analysts expect that the firm will post sales of $41.21 million, with estimates ranging from $600,000.00 to $115.64 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Kadmon.

Kadmon (NYSE:KDMN) last released its earnings results on Thursday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.50. The firm had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.90 million.

A number of equities analysts recently weighed in on KDMN shares. HC Wainwright set a $25.00 price target on Kadmon and gave the stock a “buy” rating in a research note on Monday, August 13th. ValuEngine raised Kadmon from a “hold” rating to a “buy” rating in a research note on Wednesday. WBB Securities raised Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price target on the stock in a research note on Wednesday, October 17th. Finally, Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a research note on Thursday, October 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Kadmon presently has an average rating of “Buy” and an average price target of $11.43.

Several institutional investors have recently made changes to their positions in the company. Vivo Capital LLC lifted its holdings in shares of Kadmon by 213.6% during the 2nd quarter. Vivo Capital LLC now owns 10,454,545 shares of the company’s stock valued at $68,919,000 after buying an additional 7,121,212 shares during the last quarter. Acuta Capital Partners LLC lifted its holdings in Kadmon by 52.3% in the 2nd quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the company’s stock worth $36,149,000 after purchasing an additional 3,110,014 shares during the last quarter. BlackRock Inc. lifted its holdings in Kadmon by 209.3% in the 2nd quarter. BlackRock Inc. now owns 4,763,436 shares of the company’s stock worth $19,005,000 after purchasing an additional 3,223,211 shares during the last quarter. Millennium Management LLC lifted its holdings in Kadmon by 490.1% in the 1st quarter. Millennium Management LLC now owns 1,847,444 shares of the company’s stock worth $7,852,000 after purchasing an additional 1,534,371 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in Kadmon by 63.6% in the 2nd quarter. Marshall Wace LLP now owns 1,704,894 shares of the company’s stock worth $6,803,000 after purchasing an additional 662,773 shares during the last quarter. Institutional investors and hedge funds own 69.65% of the company’s stock.

Shares of KDMN opened at $2.69 on Friday. The stock has a market capitalization of $300.85 million, a P/E ratio of -1.89 and a beta of 3.57. Kadmon has a 1-year low of $1.88 and a 1-year high of $5.86.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Recommended Story: Asset Allocation

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply